Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Transtibial Amputation - Unilateral
Interventions: MIT Variable Stiffness Prosthesis v1, MIT Variable Equilibrium Angle Prosthesis v1, MIT Sliding Beam Passive Prosthesis, Ossur Pro-Flex XC, Blatchford Elan Variable-Dampening Prosthesis, Ossur Proprio Variable Angle Prosthesis, MIT Variable Stiffness Prosthesis v2, MIT Variable Equilibrium Angle Prosthesis v2; Device
Lead sponsor: Massachusetts Institute of Technology; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Burlington, Massachusetts • Cambridge, Massachusetts

Conditions: Diabetic Foot Ulcer
Interventions: 0.75% MDI-1228_mesylate gel plus Standard of Care, Standard of Care Alone; Drug · Other
Lead sponsor: Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus Type 2
Interventions: pioglitazone, taspoglutide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 57
States / cities: Buena Park, California • Chino, California • Los Angeles, California + 52 more

Conditions: Erythema, Drainage, Bruising, Pain
Interventions: Insorb staples, metal staples (Ethicon metal stapler); Device
Lead sponsor: Orthopaedic Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healing
Interventions: Shapes by PolyMem dressing, Shapes by PolyMem Silver Dressing, Shapes by PolyMem on one site and Shapes by PolyMem Silver dressing on second site; Device
Lead sponsor: Ferris Mfg. Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: Intensive control of SBP, Standard control of SBP; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 50 Years and older
Enrollment: 9,361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Melanoma
Interventions: Ipilimumab, Chemotherapy; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • Aurora, Colorado • Indianapolis, Indiana + 4 more

Conditions: Plague, Pneumonic, Plague, Vaccine-Preventable Diseases
Interventions: rF1V-1018, rF1V vaccine; Biological
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Burns
Interventions: Sulfamylon® For 5 % Topical Solution, Topical Antimicrobial/Antifungal Medications; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 3 Months and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 9
States / cities: Mobile, Alabama • Redlands, California • Gainesville, Florida + 6 more

Conditions: Ocular Infection
Interventions: DCN01, Unisol; Drug
Lead sponsor: Deacon Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Dry Mouth
Interventions: Marketed Dry Mouth Rinse, Water control, Experimental Dry Mouth Rinse; Device · Other
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Obesity, Respiratory Insufficiency, Right-Sided Heart Failure, Pulmonary Atelectasis, Respiratory Mechanics
Interventions: PEEP INCREMENTAL, PEEP DECREMENTAL; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Scar, Hypertrophic Scar
Interventions: Botulinum Toxin, Normal saline; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: End Stage Renal Disease (ESRD)
Interventions: Not listed
Lead sponsor: Merit Medical Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: QT Interval
Interventions: Telotristat etiprate, Placebo, Moxifloxacin; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Hepatitis B, Chronic
Interventions: peginterferon alfa-2a [Pegasys]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 6
States / cities: San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Hazardous Drinking, Posttraumatic Stress Disorder
Interventions: Alcohol-PTSD-PFI (AP-PFI), Active Comparison Condition (C-PFI); Other
Lead sponsor: University of Houston; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Sarah Blair, M.D.; Other
Eligibility: Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: La Jolla, California • San Diego, California

Conditions: Chronic Pain, Pain, Widespread Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury
Interventions: Pain Ed, CBT for Pain, Usual Care; Behavioral · Other
Lead sponsor: University of Alabama, Tuscaloosa; Other
Eligibility: 19 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Tuscaloosa, Alabama • Greenville, North Carolina

Conditions: Shoulder Pain
Interventions: interscalene nerve catheter; Device
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Heavy Drinking, Mental Health Wellness
Interventions: Personalized Normative Feedback; Behavioral
Lead sponsor: RAND; Other
Eligibility: 18 Years to 40 Years
Enrollment: 754 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Postoperative Nausea and Vomiting
Interventions: Ondansetron, Vestipitant; Drug
Lead sponsor: Accenture; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 7
States / cities: Sheffield, Alabama • Phoenix, Arizona • Boynton Beach, Florida + 3 more

Conditions: Cardiovascular Diseases
Interventions: Active choice, Social comparison feedback; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 40 Years to 75 Years
Enrollment: 4,774 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hormone Replacement Therapy
Interventions: Estradiol acetate, Estradiol, Conjugated equine estrogens; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 32
States / cities: Phoenix, Arizona • Carmichael, California • San Diego, California + 28 more

Search by objective public record fields.

Comparison of Various Prosthetic Foot-Ankle Mechanisms

A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

A Comparison of INSORB Staples With Metal Staples in Total Hip Replacement

Evaluation of Preferences of Consumers and Clinicians for the Management of Shave Biopsy Sites With a PolyMem Formulation Dressing or Current Standard of Care.

Systolic Blood Pressure Intervention Trial

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group

A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers

A Pilot Study to Assess Dry Mouth Relief After Using an Experimental Mouth Rinse

Open Lung Strategy in Critically Ill Morbid Obese Patients

Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization

HeRO Graft Compared to Permanent Catheters for End Stage Renal Disease (ESRD) Patients Receiving Hemodialysis

A Thorough QT Study of Telotristat Etiprate

A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B

PFI Hazardous Drinkers With Subclinical PTSD

Study to Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade

Literacy-Adapted Psychosocial Treatments for Chronic Pain --- "Learning About Mastering/My Pain"

A Study Comparing Two Methods of Placing an Interscalene Nerve Catheter for Postoperative Pain Control in Patients Who Undergo Open Shoulder Surgery.

Brief Online Intervention for Veterans

A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)

Pragmatic, Randomized Evaluation of Statin Active Choice to Reach Improved Outcomes Based on Evidence

Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.